Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Company stock crossed $50/share after strong earnings. The company saw 18% YoY revenue growth in 2Q 2024. Bristol-Myers has a strong pipeline with potential for future growth, focusing on debt reduction and shareholder returns.

Bristol-Myers Squibb Earnings Reinforces Our Thesis

AbbVie

Amgen

AstraZeneca

Johnson & Johnson

Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.

Pharma companies less concerned after hearing from US on negotiated prices for Medicare

Bristol-Myers Squibb Co BMY on Friday reported upbeat second-quarter results.

Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings

Bristol-Myers Squibb NYSE: BMY is in the healthcare sector and is the 10th largest pharmaceutical firm in the world by market capitalization. The company released Q2 2024 financial results on July 26, 2024.

Pharma Giant's Shares Up After Impressive Q2 Earnings Release

Gilead Sciences

Pfizer

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Eli Lilly

Novo Nordisk

A market rotation is playing out across large pharmaceutical companies, with industry laggards such as Bristol Myers Squibb BMY 11.44%increase; green up pointing triangle soaring in recent weeks and richly valued obesity plays Eli Lilly LLY -2.02%decrease; red down pointing triangle and Novo Nordisk NOVO.B 0.95%increase; green up pointing triangle sinking. But these moves are about more than just momentum: It is also helping that the industry seems to be weathering regulatory storms well.One of the biggest concerns for pharmaceutical companies in recent years has been drug-pricing pressure stemming from the Inflation Reduction Act (IRA), which for the first time empowered Medicare to directly negotiate how much it pays for some high-price therapies.

Big Pharma Rallies and Moves Past Obesity

AT&T

Verizon

Whirlpool

24/7 Wall St. Insights Dividend stocks will outperform when the Federal Reserve starts to lower rates in September.

6 Blue Chip Dividend Stock Bargains to Buy Now That All Yield 5% and More

Bristol Myers Squibb's Q2 2024 revenue increased 9% year-over-year, reaching $12.2 billion. Newer drugs like Reblozyl and Opdualag demonstrated strong revenue growth in Q2, 2024. Despite facing patent cliffs, BMS's up-and-coming assets like Reblozyl, Breyanzi, and KarXT for schizophrenia offer promising future revenue potential.

Bristol Myers Squibb Shows Resilience Amid Patent Expiry Challenges (Rating Upgrade)

Dividend yields have historically been a strong predictor of stock returns over long periods. Current market conditions could be ripe for a rally in high-yield equities.

2 High-Yield Dividend Stocks That Could Shine in 2025

Bristol-Myers Squibb had a strong Q2 earnings report, backed by strong momentum in both legacy and new products. The management has boosted its guidance for the remainder of 2024, enhancing confidence in the safety of the stock's stellar 5% dividend yield. Seasonality trends suggest that the stock usually performs much better in the second half of a year.

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

The drugmaker's newest therapies are seeing unexpectedly strong sales growth. Its legacy drug portfolio, meanwhile, is still a solid cash cow.

Why Bristol Myers Squibb Jumped Nearly 10% on Friday

Celgene

Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Head of Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Chris Shibutani - Goldman Sachs Tim Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Carter Gould - Barclays Seamus Fernandez - Guggenheim Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Trung Huynh - UBS Matthew Phipps - William Blair Olivia Brayer - Cantor Fitzgerald Steve Chesney - Redburn Atlantic James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Sean McCutcheon - Raymond James Alexandria Hammond - Bank of America Operator Good day and welcome to the Bristol Myers Squibb Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Bristol-Myers Squibb Company (BMY) Q2 2024 Earnings Call Transcript

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday.

Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results

Colgate-Palmolive

T. Rowe Price Group

PCE/Core PCE Inflation In Line With Estimates in June.

PCE/Core PCE Inflation In Line With Estimates in June

Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.

Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View

Bristol Myers Squibb stock gapped higher Friday after the Big Pharma stalwart beat June-quarter forecasts and raised its outlook.

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win

Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.

Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Revenue for the quarter was $12.2 billion, a 9% increase year over year. Non-GAAP EPS rose to $2.07, an 18% increase from the previous year's $1.75.

Bristol Myers Squibb Raises Outlook After Solid Q2 Earnings

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.75 per share a year ago.

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

Global sales of Eliquis, a drug used to reduce the risk of stroke and blood clots, increase 7% in the second quarter from a year earlier.

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings.

Bristol Myers Squibb earnings easily topped Q2 views, fueled by cost cuts and blockbuster drug Eliquis. Bristol Myers stock jumped.

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps

Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.

Bristol Myers second-quarter results beat expectations, helped by new drugs

Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thinner Eliquis and a portfolio of drugs it expects to help it deliver long-term growth.

News for Bristol-Myers Stock (BMY)